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Background and Purpose: Multiple members of the thiol isomerase (TI) family of
enzymes are present in and released by platelets. Inhibition of these enzymes results
in diminished platelet responses, aggregation, adhesion and thrombus formation.
Recently, the therapeutic potential of TI inhibition has been recognised and drug-
development technologies were used to identify selective small molecule inhibitors.
To date, few pan-TI inhibitors have been characterised and the most studied, bacitra-
cin, is known to be nephrotoxic, which prohibits its systemic therapeutic usage.
Experimental Approach: We therefore sought to identify novel broad-spectrum
inhibitors of these enzymes and test their effects in vivo. A total of 3,641 compounds
were screened for inhibitory effects on the redox activity of ERp5, protein disulphide
isomerase (PDI), ERp57, ERp72 and thioredoxin in an insulin turbidity assay. Of the
lead compounds identified, zafirlukast was selected for further investigation.
Key Results: When applied to platelets, zafirlukast diminished platelet responses in
vitro. Zafirlukast was antithrombotic in murine models of thrombosis but did not
impair responses in a model of haemostasis. Since TIs are known to modulate adhe-
sion receptor function, we explored the effects of zafirlukast on cell migration. This
was inhibited independently of cysteinyl LT receptor expression and was associated
with modulation of cell-surface free thiol levels consistent with alterations in redox
activity on the cell surface.
Conclusion and Implications: We identify zafirlukast to be a novel, potent, broad-
spectrum TI inhibitor, with wide-ranging effects on platelet function, thrombosis and
integrin-mediated cell migration. Zafirlukast is antithrombotic but does not cause
bleeding.
Abbreviations: CysLT, cysteinyl leukotriene; CysLTR, cysteinyl leukotriene receptor; MPB, Nα-(3-maleimidylpropionyl)biocytin; PDI, protein disulphide isomerase; TI, thiol isomerase; ZFL,
zafirlukast.
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1 | INTRODUCTION
Thrombosis-related pathologies such as myocardial infarction, stroke,
pulmonary embolism or deep vein thrombosis are the primary cause
of mortality for much of the Western world (Furie & Furie, 2012),
highlighting the importance of identifying new therapeutic targets to
treat these diseases. One such interesting target is protein disulphide
isomerase (PDI), which, when inhibited, attenuates both arterial and
venous thrombosis, unlike current clinically used therapies (Cho
et al., 2012; Jasuja et al., 2012). Protein disulphide isomerase is the
most well-studied member of a family of thiol isomerases (TIs) that
includes ERp5 (Jordan et al., 2005), ERp57 (Holbrook et al., 2012),
ERp72 (Holbrook et al., 2018), ERp44, TMX3 and thioredoxin
(Holbrook et al., 2010), which are found on the surface of platelets
and involved in the propagation of platelet activation and subsequent
thrombus formation. Using inhibitory antibodies that are selective for
cell-surface protein disulphide isomerase (Essex & Li, 1999; Lahav
et al., 2002), ERp5 (Jordan et al., 2005), ERp57 (Holbrook et al., 2012)
or ERp72 (Holbrook et al., 2018), thiol isomerase (TI) inhibition has
been shown to result in decreased platelet aggregation, granule secre-
tion, integrin activation, integrin-mediated adhesion and thrombus
formation.
Much work has focused on identifying specific small molecule
inhibitors of protein disulphide isomerase, including quercetin ana-
logues (isoquercetin and rutin) (Jasuja et al., 2012; Stopa et al., 2017),
BAP2 analogues (Yang et al., 2019) and bepristats (Bekendam
et al., 2016; Khodier et al., 2013), which all inhibit thrombus formation
and fibrin generation in mice, while isoquercetin has been demon-
strated to have clinical potential in phase II clinical studies (Stopa
et al., 2017; Zwicker et al., 2019).
We have previously shown that while inhibition of specific
platelet thiol isomerase results in broadly similar impact on platelet
activation and thrombosis, these effects are not identical suggesting
different substrates and/or mechanisms of action and therefore each
thiol isomerase could be an independent target (Holbrook
et al., 2012; Holbrook et al., 2018). Importantly, the effects of plate-
let thiol isomerases are non-redundant, where addition of one family
member is unable to rescue the absence of another (J. Zhou
et al., 2017), again suggesting distinctive modes of action. Given the
non-redundant roles of these enzymes, it is important to determine
if broad-spectrum inhibition is an effective therapeutic strategy and
to determine its effects in vivo with respect to prevention of throm-
bosis without compromising haemostasis. To date, the only known
broad-spectrum thiol isomerase inhibitor is the antibiotic bacitracin,
which is limited to topical use due to nephrotoxicity (Michie, Zintel,
Ma, Ravdin, & Ragni, 1949). Thus, in this study, we sought to iden-
tify new family-wide (pan) inhibitors that may show promise for
human disease prophylaxis. We report that the structurally related
cysteinyl LT (CysLT ) receptor antagonists zafirlukast and
montelukast are powerful inhibitors of thiol isomerase activity.
Zafirlukast, the more potent inhibitor, was found to modulate plate-
let function and integrin function in vitro and inhibit thrombosis in
mice while bleeding was unaffected.
2 | METHODS
Cross-linked collagen-related peptide (CRP-XL) was purchased from
Prof Richard Farndale (University of Cambridge, Cambridge, UK)
and Horm collagen (type I) from Nycomed, Germany. Chronolume
ATP standard reagents were from Chronolog (Havertown, PA,
USA). Montelukast (MTL), zafirlukast (ZFL), bovine insulin and baci-
tracin were purchased from Sigma Aldrich (Poole, UK). Fura-2 AM,
normal goat serum, Nα-(3-maleimidylpropionyl)biocytin (MPB) and
phalloidin Alexa-Fluor 568 conjugate were from Thermo Fisher Sci-
entific (Leicestershire, UK). Anti-GPIb DyLight 649-conjugated anti-
body (Cat# X649) and anti-mouse P-selectin-FITC conjugate (Cat#
D200) were from Emfret Analytics (Germany). Anti-human
fibrinogen-FITC conjugate was from Dako (Cambridgeshire, UK)
and anti-human P-selectin-PE conjugate (Cat# 555524, RRID:
AB_395910) was obtained from BD Biosciences (Oxford, UK).
What is already known
• Platelets contain multiple TIs which are key to the regula-
tion of platelet activation and thrombosis.
• No pan-TI inhibitors that are safe and tolerated in vivo
are therapeutically available.
What this study adds
• Zafirlukast inhibited multiple TI and platelet function
in vitro and in vivo.
• Zafirlukast inhibits cell migration through redox modifica-
tions of cell-surface proteins.
What is the clinical significance
• Zafirlukast shows antithrombotic effects without affect-
ing haemostasis.
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Streptavidin-HRP conjugate (Cat# ab7239, RRID:AB_305786) was
from Abcam (Cambridge, UK). Vectashield antifade mounting
medium was from Vector Laboratories (Cat# H-1000, RRID:
AB_2336789, Peterborough, UK).
2.1 | Insulin-based turbidometric assay
Initial compound library screening was performed in an insulin
turbidity assay adapted for high-throughput screening
(Holmgren, 1979; Smith et al., 2004). The reduction of the dis-
ulphide bond in insulin by a thiol isomerase results in the separa-
tion of the A and B chains and precipitation, which is measured by
spectrophotometry at a wavelength of 650 nm. Using Corning
3891 well plates (with a final volume of 10 μl), a final concentra-
tion of 10 μgml−1 of ERp57, 125-μM insulin and 2-mM EDTA in
potassium phosphate buffer (100 mM) was added to each experi-
mental well. Bacitracin (3 mM) was added to select wells as a posi-
tive control and vehicle plates served as a negative control.
Experimental compounds were pin transferred to the wells at a
final concentration of 30 μM and plates shaken. After incubation
for 10 min, 0.3-mM DTT was added to propagate enzyme activity.
Following reaction for 1 hr at 37C, plates were read using a
PerkinElmer Envision plate reader (PerkinElmer, Waltham, MA). All
compounds were tested in duplicate at the ICCB-Longwood
Screening Facility at Harvard Medical School.
Lead compounds were diluted in a 6-point dose curve (concentra-
tions depending on the observed effects in the initial screen) and insulin
turbidity was measured kinetically each minute for 75 min using a
Spectramax M3 microplate reader (Molecular Devices, Sunnyvale, CA).
Specificity assay also utilised the insulin turbidity assay to determine
specificity of inhibition; ERp57 was replaced with PDI (10 μgml−1),
ERp5 (30 μgml−1), ERp72 (10 μgml−1) or thioredoxin (10 μgml−1), to
determine the ability of lead compounds to inhibit these enzymes.
2.2 | Platelet preparation and stimulation
Washed human platelets from consenting, drug-free donors were pre-
pared by differential centrifugation as described previously (Holbrook
et al., 2018) and suspended to a density of 4 × 108 cellsml−1 in
Tyrodes-HEPES buffer (134-mM NaCl, 2.9-mM KCl, 0.34-mM
Na2HPO4, 12-mM NaHCO3, 20-mM HEPES, 1-mM MgCl2 and 5-mM
glucose, pH 7.3). Prior to stimulation, platelets were incubated with
zafirlukast or vehicle (DMSO, 0.1% v/v) for 5 min. Platelets were stim-
ulated with agonists for 180 s in a lumi-aggregometer (Chronolog,
Havertown, PA, USA) with continuous stirring. Mouse blood was
obtained on the day of experimentation by cardiac puncture following
termination by increasing concentrations of CO2. PRP was isolated
from anticoagulated (4% w/v sodium citrate) blood by centrifugation
at 200 g for 8 min. Platelets were pelleted by centrifugation at 1,000 g
for 5 min in the presence of 100 ngml−1 PGI2 and re-suspended to a
density of 2 × 108 cellsml−1 inTyrodes-HEPES buffer.
2.3 | Platelet granule secretion and calcium
mobilisation measurements
P-selectin exposure in human and mouse platelets was measured by
flow cytometry and calcium mobilisation in human platelets assayed
as described previously using Fura-2 AM (Holbrook et al., 2018). ATP
secretion from dense granules was measured using lumi-
aggregometry (Holbrook et al., 2012).
2.4 | Assessment of arterial thrombus formation
and tail bleeding assay
Male C57BL/6J mice (RRID:IMSR_JAX:000664 bred in house, at
age 4–5 weeks with a weight range of 19–25 g) were
anaesthetised by intraperitoneal injection of ketamine (125 mgkg−1),
xylazine (12.5 mgkg−1) and atropine (0.25 mgkg−1). Platelets were
labelled by intravenous infusion of DyLight 649-conjugated anti-
GPIb platelet labelling antibody (0.2 μgg−1 body weight). Following
exposure of the testicular cremaster muscle, vehicle (DMSO, 0.1%
v/v) or zafirlukast (20 μMml−1 of blood volume) was infused intra-
venously and following a 5-min incubation period, arteriole wall
injury was induced by ablation laser (Micropoint, Andor Technology,
Belfast, UK). Thrombi were observed using an Olympus BX micro-
scope (Olympus, Essex, UK) and a Hamamatsu (Hamamatsu Photon-
ics, Hertfordshire, UK) CCD camera and data analysed using
Slidebook Software version 5.0 (Intelligent Imaging Innovations,
Denver, USA) (Falati et al., 2006; Holbrook et al., 2018; Holbrook
et al., 2012). Mice were killed using Schedule 1 approved methods
at the end of the experiment. For tail bleeding assays, female
C57BL/6J mice, bred in house (RRID:IMSR_JAX:000664, 6–8 weeks
old, 21–30 g), were anaesthetised by intraperitoneal injection of
ketamine (125 mgkg−1), xylazine (12.5 mgkg−1) and atropine
(0.25 mgkg−1), and drug or vehicle infused into the femoral vein
5 min prior to tail biopsy. Following drug treatment, 0.5 cm of tail
tip was excised and blood collected into sterile PBS. Time to bleed-
ing cessation was recorded. Mice were killed when bleeding had
ceased or at 20 min' post tail tip excision. All animal experiments
were blinded for both the experimental treatment and the analysis.
Animal experiments were approved by the University of Reading
Local Ethical Review Panel and authorised by the UK Home Office.
Animal studies are reported in compliance with the ARRIVE guide-
lines (Percie du Sert et al., 2020) and with the recommendations
made by the British Journal of Pharmacology (Lilley et al., 2020).
2.5 | Cell migration scratch assays
MDA-MB-231 (ATCC Cat# HTB-26, RRID:CVCL_0062) or HEK293T
(ATCC Cat# CRL-3216, RRID:CVCL_0063) were seeded into wells of
a 12-well plate (fibronectin coated, 10 μgml−1) and grown to conflu-
ence in DMEM supplemented with 10% (v/v) FBS and 1% (v/v)
penicillin–streptomycin. Following aspiration of media, a vertical
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scratch was performed to bisect the well and detached cells were
removed by PBS washes. Vehicle (DMSO, 0.1% v/v) or zafirlukast was
added to each well in the presence of DMEM with 1% (v/v) FBS, and
wells were imaged at 1, 4, 16, and 37 hr (MDA-MB-231) or 1, 4, 20 or
40 hr (HEK293T) post-scratch using a Zeiss A1 Axiovert Inverted
Epifluorescent microscope with a ×5 Planar Plan Neofl Ph1 0,15
∞ /0,17 objective. Images were analysed using Zeiss Axiovision soft-
ware, and closure areas calculated using Fiji ImageJ. At 37/40 hr post-
scratch, cells were fixed in 4% (v/v) paraformaldehyde for 20 min and
permeabilised with 0.2% (v/v) Triton X-100 for 10 min. Cells were sta-
ined with phalloidin-568 (dilution of 1:250, in PBS) for 1 hr and fol-
lowing washes, counterstained with DAPI (1:1,000) for 20 min. Cells
were washed in PBS and mounted using Vectashield H-1000.
2.6 | Labelling of cell-surface thiols
MDA-MB-231 or HEK293T cells were cultured and treated as
described before. Four hours post-treatment, cells were washed with
PBS, and free thiols labelled by incubation with MPB (100 μM) for
20 min. Free label was removed by multiple PBS washes, and cells
were lysed in reducing sample treatment buffer for SDS-PAGE analy-
sis. Thiol labelling was detected using streptavidin-HRP conjugate
(1:10,000 dilution in 5% [w/v] BSA/TBS-T), and chemiluminescence
captured following the addition of ECL substrate.
2.7 | Proliferation assays
MDA-MB-231 or HEK293T cells were seeded at a density of 2.5 × 105
cells per well in a six-well cell culture plate and grown for 24 hr. Vehicle
(DMSO, 0.1% v/v) or zafirlukast was then added for a further 72 hr. Fol-
lowing drug treatment, wells were washed and cells manually counted
by haemocytometer or automatically using a Coulter counter (Beckman
Coulter, CA, USA). Cell growth inhibition was calculated by comparing
the counts of drug treated cells with untreated (control) cells as
described previously (Kennedy et al., 2007).
2.8 | Data analysis
Data were analysed using GraphPad Prism software, and statistical
analysis was performed using one-way ANOVA with a Dunnett’s
post-test or Student's unparied t-test as appropriate. Intravital data
were additionally analysed using Mann–Whitney U test. Power calcu-
lations were used for determining the appropriate sample size for tail
bleeding assays with the following criteria used: a calculated effect
size of 1.78, significance level of 0.05, and a power of 95%. Non-
normalised data were used for statistical analysis. Data where
P < 0.05 were considered significant. Post hoc tests were only con-
ducted if F in ANOVA analyses achieved P < 0.05 and there was no
significant variance in homogeneity. Sample sizes subjected to statisti-
cal analysis were at least 5 per group (n=5), where n=number of
independent values. The data and statistical analysis comply with the
recommendations of the British Journal of Pharmacology on experi-
mental design and analysis in pharmacology.
2.9 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY http://www.guidetopharmacology.org, and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2019).
3 | RESULTS
3.1 | Zafirlukast is a potent, broad-spectrum thiol
isomerase inhibitor
A total of 3,641 compounds were assayed for their ability to inhibit
ERp57 activity by insulin turbidity assay. Initial screen data were
cross-checked against databases of compounds with known false pos-
itive readouts, and consequently, 11 compounds selected as potential
leads. These compounds were assayed for time-dependent enzyme-
inhibitory activity of the other known platelet thiol isomerases PDI,
ERp5, ERp72 and thioredoxin. A compound of particular interest,
zafirlukast, from the CysLT receptor antagonist family was found to
exert inhibition on all enzymes tested (Figure 1). Additionally, the
effects of the related CysLT receptor antagonist montelukast were
explored (Figure S1). The insulin turbidity assay was also repeated to
measure the effects of zafirlukast in this assay in the absence of
enzyme. Zafirlukast did not cleave insulin or alter its optical properties
in solution (Figure 1a).
Despite zafirlukast (Figure 1b–f) and montelukast (Figure S1)
exhibiting differing potencies, both compounds (at the highest con-
centration tested of 300 μM) were able to almost entirely ablate the
enzyme activity of PDI, ERp57 and thioredoxin.
Both zafirlukast and montelukast are FDA-approved treatments
for the prevention of asthma (marketed as Accolate and Singulair,
respectively). Both drugs are clinically tolerated well, can be adminis-
tered orally for long-term therapy and show little toxicity. In addition to
their role in CysLT receptor function, we demonstrate a novel role for
zafirlukast and montelukast as potent thiol isomerase inhibitors. Since
zafirlukast showed higher potency than montelukast in the insulin tur-
bidity assay, we focused our functional studies on the use of zafirlukast.
3.2 | Zafirlukast inhibits platelet aggregation and
granule secretion
Supplementation of platelet suspensions with the recombinant
enzymes PDI (J. Zhou et al., 2015), ERp72 (J. Zhou et al., 2017) or
ERp57 (Wu et al., 2012) potentiates platelet aggregation and
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inhibition or ablation of these enzymes impairs platelet responses
(Essex & Li, 1999; Holbrook et al., 2018; Holbrook et al., 2012). The
data presented in Figure 1 demonstrate that ZFL acts as a potent
inhibitor of multiple thiol isomerases, therefore we sought to confirm
the effects of zafirlukast on platelet activation. Platelet aggregation
was measured in washed platelet suspensions in the presence of
either vehicle (DMSO, 0.1% v/v) or zafirlukast (0.1–10 μM) and stimu-
lated for 180 s with collagen (1 μgml−1, Figure 2a,b). zafirlukast treat-
ment (10 μM) decreased platelet aggregatory responses by 85%
(±4.17%), 5 μM reduced aggregation by 78% (±7.37%), 2.5 μM by 53%
(±10.56%), 1.25 μM by 35% (±10.9%) and 0.6 μM decreased aggrega-
tion to 35% (±10.66%). Platelet aggregation in response to collagen
had an IC50 value of 1.66 μM. Platelet aggregation was also measured
using thrombin (0.1 U) as an agonist, which showed zafirlukast to be
less potent at inhibiting this pathway of platelet activation compared
with collagen (calculated IC50 of 79.2 μM) (Figure 2c). Raw data for
mean platelet responses are presented in Figure S2.
Thiol isomerase inhibition is known to impair integrin αIIbβ3 acti-
vation and conformational changes leading to diminished fibrinogen
ligation (Holbrook et al., 2018; Holbrook et al., 2012). The effects of
zafirlukast on platelet surface fibrinogen binding were therefore mea-
sured using flow cytometry with platelet populations gated on
unstained and unstimulated cells (mean fluorescence intensity of
178 ± 3.57 AU). Vehicle samples had a mean fluorescence intensity of
4,106 ± 499.2. Zafirlukast pretreatment (10 μM) significantly reduced
fibrinogen binding to platelets and therefore integrin activation by
50% (2043 ± 165.4 AU, Figure 2d). A higher concentration of 20-μM
zafirlukast inhibited fibrinogen binding further causing 61% inhibition
(1,633 ± 161.8 AU). Incubation with lower concentrations of
zafirlukast (0.1–5 μM) showed a trend towards inhibition but did not
reach significance.
Dense granules secrete secondary mediators of platelet activation
such as ADP which underpin platelet activation and aggregation. Pre-
vious studies have shown that this process is reliant on thiol isomer-
ase family members (Holbrook et al., 2018; Holbrook et al., 2012;
Jordan et al., 2005; Robinson, O'Neill, Kiernan, O'Donoghue, &
Moran, 2006). Dense granule secretion was measured in human plate-
lets pre-incubated with varying concentrations of zafirlukast
(0.6–10 μM) and stimulated with collagen (1 μgml−1). Zafirlukast
treatment (10 μM) reduced ATP secretion by 63% (±3.72%)
F IGURE 1 Zafirlukast (ZFL) is a broad-spectrum thiol isomerase inhibitor. A total of 3,641 compounds were screened for inhibitory effects on
the redox activity of ERp5, protein disulphide isomerase (PDI), ERp57, ERp72 and thioredoxin (TRX), all assayed at 10 μgml−1 except ERp5 which
was assayed at 30 μgml−1. ZFL was selected for further investigation. The ability of zafirlukast to inhibit thiol isomerase activity and its specificity
was measured by insulin turbidity assay in which insulin chain precipitation through disulphide bond reduction was measured at a wavelength of
650 nm in a spectrophotometer at 37C. (a) Enzyme assays performed in the absence of enzyme with drug only. Zafirlukast concentration
dependently inhibits (b) PDI, (c) ERp57, (d) ERp72, (e) ERp5 and (f) thioredoxin (TRX) activity
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(Figure 3a,b). IC50 was calculated to be 8.99 μM for dense granule
secretion.
In contrast to the sensitivity of dense granule secretion to thiol
isomerase inhibition, α-granule secretion can be differentially regu-
lated by different members of the thiol isomerase family. ERp5 and
ERp72 inhibition results in substantial α-granule secretion impairment
whereas inhibition of ERp57 and PDI has little or no effect, supporting
the notion that different thiol isomerases act in subtly different man-
ners (Holbrook et al., 2018; Holbrook et al., 2012; Jordan et al., 2005;
Kim et al., 2013). Since platelet aggregation and the requisite integrin
activation and fibrinogen ligation are dampened by zafirlukast, it was
important to determine if secondary mediator secretion from
α-granules was affected in human (Figure 3c) and mouse platelets
(Figure 3d). Unstained and unstimulated platelets were used to gate
the platelet population with mean fluorescence intensity values of
305 ± 2.11 (human platelets) and 165.5 ± 1.88 (mouse platelets).
P-selectin exposure in response to cross-linked collagen-related pep-
tide (CRP-XL; 0.25 μgml−1, human platelets) or thrombin (0.1 Uml−1,
mouse platelets) stimulation was unaffected by vehicle treatment
(mean fluorescence of 6,845 ± 436.1 AU). Zafirlukast at the
highest concentration tested (20 μM) reduced human platelet
P-selectin exposure by 50% (mean fluorescence of 3,364 ± 326.3).
Concentration-dependent inhibition was observed at all concentra-
tions above 5 μM. Mouse platelet α-granule secretion was also
impaired by zafirlukast treatment (20 μM). Mean vehicle fluorescence
levels post-stimulation were 1,012 (±110.9 AU); these were reduced
by 57% (427.1 ± 53 AU) by zafirlukast treatment.
Similar to α-granule secretion, Ca2+ mobilisation from intracellular
stores is differentially regulated by individual thiol isomerases. Neither
ERp5 nor PDI ablation reduces GPVI-stimulated Ca2+ mobilisation,
whereas ERp57 and ERp72 inhibition results in delayed responses and
lower peak levels of Ca2+ (Holbrook et al., 2018; Holbrook
et al., 2012; Jordan et al., 2005; Kim et al., 2013). In human platelets,
vehicle treatment did not impair calcium mobilisation, whereas, at the
highest concentration tested (40 μM), zafirlukast reduced Ca2+
mobilisation by 58% (±10.9%) (Figure 3e,f).
3.3 | Zafirlukast inhibits thrombosis but does not
cause bleeding
Thiol isomerase inhibition or ablation results in substantial disruption
of thrombus formation in laser injury thrombosis models (Cho, Furie,
Coughlin, & Furie, 2008; Holbrook et al., 2018; Holbrook et al., 2012;
F IGURE 2 Zafirlukast (ZFL) inhibits platelet aggregation and fibrinogen binding. Washed human platelets (4 × 108 cellsml−1) were incubated
with ZFL (0.1–10 μM) or vehicle for 5 min prior to stimulation with (a) collagen (1 μgml−1) for 180 s in an optical aggregometer. (b) Data were
normalised to vehicle, and % inhibition of aggregation (mean ± SEM) was calculated, n = 12. (c) Log aggregation response to thrombin
(0.1 Uml−1), n = 6. (d) Fibrinogen binding was measured by flow cytometry. Platelets (2 × 108 cellsml−1) were incubated with vehicle or
zafirlukast (0.1–20 μM) for 5 min prior to stimulation with 0.25 μgml−1CRP-XL. Anti-human fibrinogen-FITC conjugate was added for 20 min
(1:500 dilution), and samples were fixed with 0.2% (v/v) paraformaldehyde; data for 10,000 events were recorded, n = 6. Graphs represent
mean ± SEM. Data were analysed by one-way ANOVA, *P < 0.05,
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Passam et al., 2015; J. Zhou et al., 2017). The effects of an acute dose
of zafirlukast (20 μM) on arterial thrombus formation were deter-
mined by intravital microscopy on cremaster muscle arterioles.
Figure 4a shows time-resolved representative images of thrombi
formed in the presence of vehicle (0.1% [v/v] DMSO). Thrombi
formed in the presence of zafirlukast (20 μM) are illustrated in
Figure 4b. Figure 4c shows maximum fluorescence intensity measure-
ments for vehicle (n = 18 thrombi, black circles) or zafirlukast-treated
mice (n = 12 thrombi, red squares); thrombus size was significantly
impaired by zafirlukast treatment. Since significant and consistent
effects were observed with 12 thrombi in the zafirlukast-treated mice,
no further mice were killed. Therefore this group had fewer replicates
than the control but was still adequately powered. We assessed the
effects of zafirlukast on bleeding time, measured by murine tail bleed-
ing assay. Figure 4d shows that zafirlukast treatment (bleeding time of
243 s ± 31 s, n = 10, red squares) did not significantly prolong or
F IGURE 3 Platelet granule secretion and calcium flux in human and mouse platelets is diminished by zafirlukast (ZFL). Washed human
platelets (4 × 108 cellsml−1) were incubated with ZFL (0.1–10 μM) or vehicle for 5 min prior to stimulation with collagen (1 μgml−1). Chronolume
reagent was added for 2 min prior to stimulation, and luminescence recorded. (a) Representative traces of ATP secretion, and (b) is log dense
granule secretion values, n = 5. (c) For α-granule secretion, human platelet P-selectin exposure was measured by flow cytometry. Platelets
(2 × 108 cellsml−1) were incubated with vehicle or zafirlukast (0.1–20 μM) for 5 min prior to stimulation with 0.25 μgml−1 CRP-XL. Anti-human
P-selectin PE conjugate was added for 20 min (1:500 dilution), and samples were fixed with 0.2% (v/v) paraformaldehyde, n = 6. (d) Following
incubation with vehicle or zafirlukast (0.6–20 μM), mouse platelets were stained with anti-mouse P-selectin FITC conjugate and stimulated with
thrombin (0.1 Uml−1), n = 12. For Ca2+ mobilisation assays, platelets (4 × 108 cellsml−1) were loaded with Fura-2 AM and incubated with either
vehicle or zafirlukast (2.5–40 μM) for 5 min before addition of CRP-XL (0.5 μgml−1), (e) mean Ca2+ trace. (f) peak Ca2+ concentration normalised
to vehicle values, n = 6. Graphs represent mean ± SEM; data were analysed by one-way ANOVA, *P < 0.05
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shorten bleeding times compared to vehicle treatment (bleeding time
of 225 s ± 28 s, n = 10, black circles).
3.4 | Zafirlukast inhibits cell migration by
mediation of cell-surface thiols in MDA-MB-231 and
HEK293T cells
In addition to the effects of thiol isomerases on the modulation of
platelet integrin activation, thiol isomerases are known to be impor-
tant for the modulation of integrin function in other cell types includ-
ing vascular smooth muscle cells (Tanaka et al., 2019), lymphocytes
(Bi, Hong, Lee, & Baum, 2011; Lawrence, Song, & Weber, 1996) and
cancerous cells. Numerous studies have linked enhanced cell-surface
thiol isomerase expression with increased integrin-dependent or
mediated migration, invasion of surrounding tissue, and proliferation
(Goplen et al., 2006; Hussmann et al., 2015; Li et al., 2016; Samanta
et al., 2017; Xu et al., 2012; Xu et al., 2019). Cell migration and pro-
liferation responses in scratch wound closure assays or transwell
migration assays are known to be sensitive to thiol isomerase inhibi-
tion. The PDI inhibitors PACMA31, quercetin-3-rutinoside, bacitracin
and anti-PDI antibodies all impair wound closure through a mecha-
nism that is proposed to include down-regulation of thiol disulphide
exchange in adhesion receptors containing β1 and β3 integrin sub-
units (Goplen et al., 2006; Popielarski, Ponamarczuk, Stasiak, Watala,
& Swiatkowska, 2019). Similar effects have been observed in cells
where PDI (Lin et al., 2016) or ERp57 expression has been silenced
(Li et al., 2019; Ye, Fu, Dou, & Wang, 2018), suggesting that thiol
isomerase expression is a pro-migratory and pro-survival factor and
is targetable for disruption of cancer progression in a number of solid
tumour and haematological cancer types.
We were keen to explore the effects of zafirlukast on integrin-
mediated cell migration in cell models where cells express CysLT
receptor and are known to be sensitive to thiol isomerase inhibi-
tion (MDA-MB-231) and in cells lacking CysLT receptors
(HEK293T). This would allow us to study cysteinyl LT
(CysLT)-independent actions of zafirlukast on redox-sensitive
integrin-mediated function, which is proposed to be modulated by
extracellular thiol isomerases.
Expression of the thiol isomerases PDI, ERp57, ERp72 and ERp5
was detected on “the surface of” non-permeabilised (Figure S3) and
permeabilised MDA-MB-231 cells (Figure S4). Using
F IGURE 4 Thrombus formation in vivo is inhibited by zafirlukast with no impact on bleeding times. The effects of zafirlukast (ZFL) on
thrombus formation in mice were determined following laser injury of cremaster muscle arterioles and observed by intravital microscopy. Male
C57/BL6 mouse platelets were labelled with DyLight 649-conjugated anti-GPIb antibody (0.2 μgg−1 body weight) and either vehicle (a) or
zafirlukast infused (at a volume required to achieve a circulating concentration of 20 μM) (b). Following laser injury, images were recorded for
5 min. The vessel wall is outlined in each pre-injury panel, and the red arrow indicates direction of blood flow. (c) Maximum fluorescence intensity
of each thrombus formed in vehicle-treated mice (n = 18 thrombi, black circles) or zafirlukast-treated mice (n = 12 thrombi, red squares). (d) The
effects of zafirlukast on bleeding were determined by tail bleeding assay. Vehicle or zafirlukast (at a volume required to achieve a circulating
concentration of 20 μM) was infused into the femoral veins of C57/BL6 mice, 5 min prior to tail biopsy; 0.5 cm of tail tip was excised, and blood
collected in PBS, and time to cessation of bleeding was recorded. Graphs represent mean ± SEM, n = 10 per treatment; data were analysed by
Student's t-test, *P < 0.05
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immunocytochemistry, staining for all enzymes was observed. Sec-
ondary antibody controls displayed no signal in the Alexa-Fluor
488 channel. With permeabilization, some differences in staining were
observed; PDI and ERp57 staining appeared to increase suggesting
that although a small pool of cell-surface thiol isomerase exists, a
greater pool is retained within the cells.
The effects of zafirlukast in integrin-mediated cell migration were
measured by scratch assay in which a scratch was inflicted on a mono-
layer of cells treated with either vehicle (Figure 5a) or zafirlukast
(20 μM, Figure 5b), and images recorded until successful closure of
vehicle-treated scratch wells was achieved. Figure 5c,d shows nuclear
and actin staining for wells at assay endpoint. Closure areas were
measured at 1, 4, 16 and 37 hr (Figure 5e). Compared with area values
obtained at 1 hr, vehicle-treated cells had migrated to cover over 86%
of the scratch area at endpoint (closure area of 62,163 ± 23,552)
whereas with zafirlukast treatment, cell migration was significantly
attenuated with 56% of the scratch area covered (closure area of
243,707 ± 51,057) at endpoint. The standard 3-day growth inhibition
assay was performed to determine if zafirlukast (1–30 μM) treatment
was also able to impair proliferation. At the concentration used in the
scratch assay (20 μM), zafirlukast had a minimal effect on cell prolifer-
ation and at a concentration of 30 μM, zafirlukast only modestly
reduced proliferation by around 20% (Figure 5f).
In order to confirm that this effect was associated with decreased
cell-surface redox activity, labelling of surface free thiols was per-
formed using the cell-impermeant label MPB. At assay endpoint, cells
were washed and labelled with MPB and following SDS-PAGE separa-
tion, visualisation of the biotin moiety was performed using a
streptavidin conjugate (Figure 5g). In vehicle-treated samples, many
bands were detected corresponding to multiple proteins containing
free thiols. This was reduced by 42% in the zafirlukast-treated lane
consistent with changes in the redox state of cell-surface proteins,
specifically free thiols, implicating decreased thiol isomerase reductive
function as a potential mode of action (Figure 5h).
MDA-MB-231 cells express CysLT1 and CysLT2 receptors, so in
order to exclude or determine the role of CysLT1/2 receptor on the
effects presented in Figure 5, similar experiments were performed in a
cell line that does not possess these receptors. HEK293T are known
to lack CysLT1 and LT2 receptor mRNA and as a consequence lack
CysLT receptor signalling function (Atwood, Lopez, Wager-Miller,
F IGURE 5 Thiol isomerase inhibition by zafirlukast (ZFL) prolongs scratch closure through modification of cell-surface thiols in MDA-MB-231
cells. MDA-MB-231 seeded into wells of a 12-well culture dish were grown to confluence. Wells were bisected by means of a vertical scratch,
and detached cells removed by washing with PBS. (a) Vehicle or (b) zafirlukast (20 μM) was added to each well in the presence of DMEM
supplemented with 1% (v/v) FBS, and images were recorded at 1, 4, 16, and 37 hr post-scratch; cell leading edges are denoted in red. (c,d) At
37 hr post-scratch, cells were fixed and permeabilised, then stained with phalloidin 568 for 1 hr, and following washes, counterstained with DAPI
for 20 min. Cells were washed in PBS, and Vectashield H-1000 was added prior to imaging. (e) Images were analysed using Zeiss Axiovision
software, and closure areas calculated using Fiji ImageJ, n = 9. (f) Log proliferation data after 72-hr treatment with zafirlukast of 1–30 μM (n = 6).
(g) For thiol labelling, MDA-MB-231 seeded into wells of a 12-well cell culture dish were grown to confluence, and vehicle or zafirlukast was
added to each well in the presence of DMEM supplemented with 1% (v/v) FBS. Cells were washed 4 hr post-treatment with PBS and free thiols
labelled by incubation with MPB (100 μM) for 20 min. Free label was removed by multiple PBS washes and cells lysed in reducing sample
treatment buffer for SDS-PAGE analysis. Cell-surface thiol labelling was detected using streptavidin-HRP conjugate (1:10,000 dilution in 5%
[w/v] BSA/TBS-T), and chemiluminescence captured following the addition of ECL substrate. (h) Quantification of band intensities for surface
thiol labelling (n = 9). Graphs represent mean ± SEM. Data were analysed by Student's t-test, *P < 0.05
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Mackie, & Straiker, 2011; Figueroa, Kramer, Strange, & Denton, 2019).
Similar to data presented for MDA-MB-231, expression of thiol isom-
erases was evident in both non-permeabilised (Figure S5) and per-
meabilised cells (Figure S6). In permeabilised HEK293T, staining of
PDI and ERp57 appear to be increased and change distribution com-
pared to non-permeabilised cells whereas ERp72 and ERp5 staining
appear to decrease suggesting that a greater pool of these proteins is
associated with the cell surface.
In order to explore the effects of zafirlukast on thiol isomerase-
mediated cell migration in HEK293T, scratch assays were performed,
and closure areas recorded at 1, 4, 20 and 40 hr for (Figure 6a) vehicle
and (Figure 6b) zafirlukast. At 40 hr post-scratch, vehicle-treated cells
had over 96% coverage (closure area of 80,686 [±15,705]), whereas
zafirlukast treatment attenuated migration to 32% (1,475,154
[±81,061] of the initial area, Figure 6e). Impairment of HEK293T cell
proliferation was not detected after treatment of cells with (1–30 μM)
of zafirlukast (Figure 6f). Surface MPB labelling was also decreased in
HEK293T treated with zafirlukast when compared to vehicle levels
(Figure 6g); zafirlukast caused a 47% decrease in labelling compared
with vehicle treatment (Figure 6h). These data highlight the importance
of thiol isomerases in cell migration and demonstrate that zafirlukast is
an effective inhibitor of thiol isomerase-mediated effects in both the
presence and absence of functional CysLT1/LT2 signalling pathways.
4 | DISCUSSION
The pro-inflammatory Cysteinyl leukotrienes (CysLT) (CysLTC4, LTD4
and LTE4) are formed through the 5-lipoxygenase (5-LOX)
arachidonic acid metabolism pathway as a component of host defence
in immune cells. Immune and inflammatory diseases such as asthma
are often associated with overproduction of CysLT which bind to
CysLT receptors and induce immune-type signalling. Pharmacological
antagonism of CysLT receptors (CysLT1 and CysLT2) by drugs such as
zafirlukast and montelukast is a common approach for the treatment
of chronic asthma.
Zafirlukast was first used in 1996 for the antagonism of
CysLT1 receptors present on the human airway smooth muscle
cells to prevent the pro-inflammatory effects of CysLT binding.
Zafirlukast is generally regarded to be well tolerated in both animal
safety studies and in humans with only minimal side effects being
reported for the majority of patients. Some studies have
F IGURE 6 Zafirlukast (ZFL) impairs wound closure and thiol labelling in cells lacking CysLT receptors. HEK293T seeded into wells of a
12-well culture dish (coated with fibronectin of 10 μgml−1) were grown to confluence. Wells were bisected by means of a vertical scratch, and
detached cells removed by washing with PBS. (a) Vehicle or (b) ZFL (20 μM) was added to each well in the presence of DMEM supplemented with
1% (v/v) FBS, and images were recorded at 1, 4, 20 or 40 hr post-scratch; cell leading edges are denoted in red. (c,d) At 40 hr post-scratch, cells
were fixed and permeabilised, then stained with phalloidin 568 for 1 hr, and following washes, counterstained with DAPI for 20 min. Cells were
washed in PBS, and Vectashield H-1000 was added prior to imaging. (e) Images were analysed using Zeiss Axiovision software, and closure areas
calculated using Fiji ImageJ, n = 12. (f) Log proliferation data after 72-hr treatment with zafirlukast of 1–30 μM (n = 6). (g) For surface thiol
labelling, HEK293T seeded into wells of a 12-well cell culture dish were grown to confluence, and vehicle or zafirlukast was added to each well in
the presence of DMEM supplemented with 1% (v/v) FBS. Cells were washed 4 hr post-treatment with PBS and free thiols labelled by incubation
with MPB (100 μM) for 20 min. Free label was removed by multiple PBS washes and cells lysed in reducing sample treatment buffer for SDS-
PAGE analysis. Cell-surface thiol labelling was detected using streptavidin-HRP conjugate (1:10,000 dilution in 5% [w/v] BSA/TBS-T), and
chemiluminescence captured following the addition of ECL substrate. (h) Quantification of band intensities for surface thiol labelling (n = 7).
Graphs represent mean ± SEM. Data were analysed by Student's t-test, *P < 0.05
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demonstrated that hepatic clearance of zafirlukast from the plasma
is reduced in patients with cirrhosis of the liver and in elderly
patients, so treatment of these patients with zafirlukast is not
advised. Zafirlukast is metabolised exclusively in the liver by the
cytochrome P450 isoenzyme CYP2C9. Liver clearance of zafirlukast
can be altered by co-administration with the drugs erythromycin,
theophylline or terfenadine, which reduce plasma zafirlukast levels
while aspirin enhances its plasma levels, Therefore these drugs are
not recommended in patients receiving zafirlukast treatment
(Dekhuijzen & Koopmans, 2002).
Clinical efficacy is observed when oral doses of 20 mg are given
twice daily and higher doses are tolerated. This dose has been shown
to result in a peak plasma concentration (cMax) of 697 ngml−1 at
3 hr, which is equivalent to a plasma concentration of 1.2 μM (Fischer
et al., 2000).
Platelets do not produce CysLT as they lack 5-LOX and therefore
are unable to convert arachidonic acid to CysLTs unless they are
interacting with immune cells that can generate the lipid precursor
(Laidlaw & Boyce, 2012). Healthy human donor platelets have been
shown to express the CysLT receptors CysLT1 and CysLT2, a small
pool of which are found on the cell surface (Hasegawa et al., 2010).
Following stimulation with purified CysLT, release of the eosinophil
chemotactic factor RANTES (CCL5) from platelet α-granule stores can
be detected suggesting that under inflammatory conditions, where
platelets are circulating in proximity to cells producing CysLT, CysLT
receptor stimulation can drive the secretion of platelet stored inflam-
matory mediators (Hasegawa et al., 2010). However the function of
CysLT receptors or the effects of zafirlukast on platelet function
under basal, non-inflammatory conditions is not known and is likely
only to be determined if CysLT1 null mouse platelets were available.
Through compound library screening for small molecule inhibitors
of thiol isomerases, we identified zafirlukast and montelukast as can-
didate inhibitors of multiple thiol isomerase family members in addi-
tion to their anti-asthma function. Conventionally, the activity and
functional role of thiol isomerases has been established using
function-blocking antibodies or knockout mouse models. These stud-
ies have not only revealed the importance of thiol isomerase activity
in the regulation of thrombosis and haemostasis but also provided
insight into the subtle differences in platelet signalling targeted by
each thiol isomerase enzyme. In recent years, the focus has shifted
onto the development of pharmacological thiol isomerase inhibitors
with characterisation of several inhibitors of protein disulphide isom-
erase forthcoming, some of which have entered into clinical trials. No
broad-spectrum thiol isomerase inhibitors with similar potency for
multiple enzymes that are potent anti-thrombotics and have proven
tolerance in vivo have been developed. Our study identifies zafirlukast
and montelukast to be novel inhibitors of thiol isomerase activity, and
we tested the functional consequences of pan-thiol isomerase inhibi-
tion in human and murine platelets.
Zafirlukast treatment diminished platelet aggregatory responses
and granule secretion in a concentration-dependant manner. In addi-
tion to the effects on granule secretion, zafirlukast impaired calcium
mobilisation and fibrinogen ligation to integrin αIIbβ3. Using a murine
thrombosis model, we were able to demonstrate that zafirlukast
diminished thrombosis in vivo but did not impair or enhance bleeding
suggesting that pan-thiol isomerase inhibition is tolerated and is a via-
ble therapeutic option, worthy of further exploration as many cur-
rently prescribed anti-thrombotic therapies inhibit platelet function
but also cause bleeding.
Differential regulation effects of inhibition of multiple thiol isom-
erases between different functional assays were evident with dose
response profiles not being identical in the effects observed. IC50
values obtained for platelet aggregation were around fourfold lower
(1.66 μM) than required to elicit the same level of inhibition of dense
granule secretion. Similarly, α-granule secretion required concentra-
tions of 5-μM zafirlukast or more to cause significant inhibition. Previ-
ous studies have highlighted differential effects of this nature;
antibody-mediated inhibition of ERp5 or ERp72 results in dysfunc-
tional α-granule secretion (Holbrook et al., 2018; Jordan et al., 2005),
whereas little or no effect is observed with PDI or ERp57 blockade
(Holbrook et al., 2012; Kim et al., 2013). Likewise, calcium flux is regu-
lated by ERp57 and ERp72 but not PDI or ERp5. In in vivo assays, all
thiol isomerases have been shown to be critical for initial thrombus
formation and propagation; however, curiously not all thiol isomerases
are critical for haemostasis in mice. ERp57 and ERp72 ablation results
in prolonged tail bleeding times (Wang et al., 2013; J. Zhou
et al., 2017), while, as for zafirlukast treatment of mice, PDI-deficient
mice do not show a haemostasis defect (Kim et al., 2013). We propose
that this may be a consequence of different effects of each enzyme
on individual aspects of platelet activation balanced with different
enzymes being inhibited at different zafirlukast concentrations. There-
fore, non-overlapping aspects of platelet regulation may require
greater levels of inhibitor to counterbalance the sensitive to inhibition
and insensitive to inhibition effects of each enzyme in the multiple
pathways of platelet activation.
Thiol isomerases are also important for mediating integrin confor-
mational changes associated with cell adhesion and migration. We
therefore explored the effects of zafirlukast on these processes using a
breast cancer cell lineMDA-MB-231, which has been previously shown
to be sensitive to thiol isomerase inhibition. Since HEK293T cells do
not express CysLT receptors, experiments were repeated in these cells
to determine if responses are dependent on the CysLT1 receptor. We
demonstrate that zafirlukast is able to impair cell migration regardless
of CysLT receptor expression, without impairing proliferation, and that
zafirlukast treatment results in a decrease in cell-surface thiol levels
consistent with zafirlukast eliciting redox changes at the cell surface.
Immunoblotting for surface thiol-biotinylation revealed labelling
changes in many proteins which may be substrates or targets of thiol
isomerases, proteins of great future interest to identify.
Whether zafirlukast acts on other protein targets other than thiol
isomerases in platelets, HEK293T or MDA-MB-231 cells remain to be
determined. In bronchial epithelial and astrocytoma cell lines, CysLT1
antagonists can reduce PKA signalling following nucleotide stimula-
tion of the P2Y1 purinergic receptor pathway. It is not clear if this was
through direct binding to the receptor or as a consequence of indirect
effects on cell signalling (Lau, Chow, Au, & Ko, 2011; Mamedova
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et al., 2005). Similarly, recent findings suggest that zafirlukast can
directly activate PPARγ signalling in adipocytes (Gobel et al., 2019). In
platelets, PPARγ ligands negatively regulate platelet responses
(Moraes et al., 2010). The potential effects of zafirlukast on these
pathways in platelets remain to be explored and cannot be ruled out
as additional mechanisms of zafirlukast action on platelet function.
Since the onset of this study, recent publications report that
zafirlukast may also be beneficial for the treatment of endothelial dys-
function, inflammation (X. Zhou, Cai, Liu, Wu, & Gao, 2019), glioblas-
toma (Piromkraipak et al., 2018) and bladder cancer (Nguyen
et al., 2018). It would be interesting to establish if these effects are
related to the inhibition of thiol isomerase activity.
Most inhibitors of thiol isomerases characterised to date act by
competitive binding to the substrate binding domains of the enzyme;
therefore, future studies may entail a detailed kinetic analysis of each
enzyme to determine how zafirlukast binds and modifies its activity.
Since zafirlukast is able to inhibit at least five enzymes from a family
of at least 20 thiol isomerase proteins, such elaborate studies were
beyond the scope of this study.
In summary, we provide evidence that the anti-asthma compound
zafirlukast is a potent pan-thiol isomerase inhibitor which modulates
platelet function, cell migration, and thrombosis but does not show
detrimental effects on haemostasis.
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